Literature DB >> 24138390

Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis.

V S Akshintala1, S M Hutfless, E Colantuoni, K J Kim, M A Khashab, T Li, B J Elmunzer, M A Puhan, A Sinha, A Kamal, A M Lennon, P I Okolo, M K Palakurthy, A N Kalloo, V K Singh.   

Abstract

BACKGROUND: The efficacy of many pharmacological agents for preventing post-ERCP pancreatitis (PEP) has been evaluated in randomised controlled trials (RCTs), but it is unclear which agent(s) should be used in clinical practice. Network meta-analyses of RCTs are used to simultaneously compare several agents to determine their relative efficacy and identify priority agents for comparison in future RCTs. AIM: To evaluate pharmacological agents for the prevention of PEP by conducting a network meta-analysis of RCTs.
METHODS: We searched MEDLINE, EMBASE and Cochrane Library databases for RCTs that evaluated the efficacy of agents for preventing PEP. RCTs were simultaneously analysed using random-effects network meta-analysis under the Bayesian framework to identify the best agents. The efficacy of agents was ordered according to the probability of being ranked as any of the top three best performing agents.
RESULTS: The network meta-analysis included 99 RCTs evaluating 16 agents in 25 313 patients. Topical epinephrine (adrenaline) was the most efficacious agent with 85.9% probability of ranking among the top three agents, followed by nafamostat (51.4%), antibiotics (44.5%) and NSAIDs (42.8%). However, in a sensitivity analysis including only rectal NSAIDs, NSAIDs moved from fourth rank to second (58.1%). Patients receiving topical epinephrine, compared with placebo, had a 75% reduced risk of PEP (OR 0.25, 95% probability interval 0.06-0.66).
CONCLUSIONS: Topical epinephrine and rectal NSAIDs are the most efficacious agents for preventing post-ERCP pancreatitis, based on existing RCTs. Combinations of these agents, which act on different steps in the pathogenesis of post-ERCP pancreatitis, should be evaluated in future trials.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24138390     DOI: 10.1111/apt.12534

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Value of Raw Rhubarb Solution in the Precaution of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Patients with High-Risk Factors: A Predictive Random Compared Research in One Center.

Authors:  Chong Wang; Qirui Li; Peng Ye; Sheng Zeng; Guo-Hua Li; You-Xiang Chen; Xiao-Jiang Zhou; Nong-Hua Lv
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

Review 2.  Clinical practice guideline for post-ERCP pancreatitis.

Authors:  Tetsuya Mine; Toshio Morizane; Yoshiaki Kawaguchi; Ryukichi Akashi; Keiji Hanada; Tetsuhide Ito; Atsushi Kanno; Mitsuhiro Kida; Hiroyuki Miyagawa; Taketo Yamaguchi; Toshihiko Mayumi; Yoshifumi Takeyama; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2017-06-26       Impact factor: 7.527

3.  Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee.

Authors:  Maisam Abu-El-Haija; Soma Kumar; Jose Antonio Quiros; Keshawadhana Balakrishnan; Bradley Barth; Samuel Bitton; John F Eisses; Elsie Jazmin Foglio; Victor Fox; Denease Francis; Alvin Jay Freeman; Tanja Gonska; Amit S Grover; Sohail Z Husain; Rakesh Kumar; Sameer Lapsia; Tom Lin; Quin Y Liu; Asim Maqbool; Zachary M Sellers; Flora Szabo; Aliye Uc; Steven L Werlin; Veronique D Morinville
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

4.  Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.

Authors:  Goran Hauser; Ivana Blažević; Nermin Salkić; Goran Poropat; Vanja Giljača; Zlatko Bulić; Davor Štimac
Journal:  Surg Endosc       Date:  2016-06-17       Impact factor: 4.584

Review 5.  How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis: a systematic review and meta-analysis.

Authors:  Jianhua Wan; Yuping Ren; Zhenhua Zhu; Liang Xia; Nonghua Lu
Journal:  BMC Gastroenterol       Date:  2017-03-15       Impact factor: 3.067

6.  Epinephrine in the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Preliminary Study.

Authors:  Behzad Hatami; Seyed Mohammad Hossein Kashfi; Mohammad Abbasinazari; Ehsan Nazemalhosseini Mojarad; Mohammad Amin Pourhoseingholi; Mohammad Reza Zali; Amir Houshang Mohammad Alizadeh
Journal:  Case Rep Gastroenterol       Date:  2018-04-13

7.  Length of stay overestimates severity of post-ERCP pancreatitis: Is it time to revise the consensus definition?

Authors:  Mahya Faghih; Amitasha Sinha; Robert A Moran; Elham Afghani; Yuval A Patel; Andrew C Storm; Ayesha Kamal; Venkata S Akshintala; Atif Zaheer; Anthony N Kalloo; Vivek Kumbhari; Mouen A Khashab; Vikesh K Singh
Journal:  Endosc Int Open       Date:  2018-07-04

8.  Can topical epinephrine application to the papilla prevent pancreatitis after endoscopic retrograde cholangiopancreatography? Results from a double blind, multicentre, placebo controlled, randomised clinical trial.

Authors:  Adriana Fabiola Romano-Munive; J Jesus García-Correa; Luis F García-Contreras; José Ramírez-García; Luis Uscanga; Varenka J Barbero-Becerra; Carlos Moctezuma-Velázquez; Jorge A Ochoa-Rubí; Julio Toledo-Cuque; Gerardo Vázquez-Anaya; Daniel Keil-Ríos; Guido Grajales-Figueroa; Miguel Ángel Ramírez-Luna; Francisco Valdovinos-Andraca; Luis Eduardo Zamora-Nava; Felix Tellez-Avila
Journal:  BMJ Open Gastroenterol       Date:  2021-02

9.  Rectal NSAIDs-based combination modalities are superior to single modalities for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis.

Authors:  Tae Young Park; Hyun Kang; Geun Joo Choi; Hyoung-Chul Oh
Journal:  Korean J Intern Med       Date:  2022-02-16       Impact factor: 2.884

Review 10.  Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with rectal non-steroidal anti-inflammatory drugs.

Authors:  Tae Young Park; Hyoung-Chul Oh; Evan L Fogel; Glen A Lehman
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.